Deni Study: Real‐World Data on the Use of Nirogacestat in Patients With Desmoid Tumors in the French Sarcoma Group
International Journal of Cancer · 01.01.2027 · 160 (1) · 161-170
DOI: 10.1002/ijc.70672 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 28.07.2026. Verfasst von Pierre Kubicek und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Cancérologie de l'Ouest, Angers, France. Hauptthemen laut MEDLINE: Desmoid Tumors, Sarcoma. Die Arbeit nennt 35 Literaturangaben. Gefördert von: NetSarc (IRSCA & DGOS), RREPS (IRSCA & DGOS), RESOS (IRSCA & DGOS).
Abstract (Originalsprache)
The DeFi trial revealed a significant improvement in progression‐free survival (PFS) with nirogacestat in patients with desmoid tumors. The DeNi study reports outcomes of patients treated with nirogacestat through the French compassionate use program. DeNi is a retrospective, real‐world study. Outcomes included objective response, pain improvement, 1‐year PFS, and toxicity. Between February and June 2024, 55 patients with desmoid tumors were included (37 women). Data were updated until November 2025. The median age was 38.6 years (range: 18.0–66.7). The median number of previous therapies was 2, including local therapies. The median follow‐up was 21.4 months [95% CI: 19.5; 25.6]. The estimated median duration of nirogacestat treatment was 16 months. Partial response and stable disease were observed in 33 (60%) and 17 patients (31%), respectively. The 1‐year PFS rate was 76.2%, and 77.0% of patients remained without treatment change at 1 year, including patients with dose reductions. Of the 49 patients with baseline pain, 38 (78%) experienced pain improvement under nirogacestat; 35 (71%) reduced or discontinued analgesics. The most frequent side effects (all grades) were diarrhea (53%), fatigue (47%), and rash (29%). Thirteen patients (24%) required dose reduction: 11 for digestive adverse events (85%), 1 for mucositis, and 1 for fatigue with hypertension. The DeNi study confirms the clinical benefits of nirogacestat in patients with desmoid tumors, with improvements in pain and tumor shrinkage observed in 60% of patients and PFS consistent with that reported in the phase III DeFi trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institut de Cancérologie de l'Ouest, Angers, France.
- Institut de Cancérologie de l'Ouest, Nantes, France.
- Institut Bergonié, Bordeaux, France.
- Hôpital Cochin, Paris, France.
- Institut Claudius Regaud, Toulouse, France.
- Centre Oscar Lambret, Lille, France.
ORCID-Profile: Pierre Kubicek, Maud Toulmonde, Pascaline Boudou-Rouquette, Nicolas Penel, Antoine Italiano, Armelle Dufresne, Jean-Yves Blay
Förderung
- NetSarc (IRSCA & DGOS)
- RREPS (IRSCA & DGOS)
- RESOS (IRSCA & DGOS)
- EURACAN
- LYRICAN
- LabEx DEvweCAN
- Institut Convergence PLASCAN
- RHU4 DEPGYN
Zitieren
APA
Kubicek, P., Guérin-Charbonnel, C., Toulmonde, M., Boudou-Rouquette, P., Thibaud, V., Penel, N., Italiano, A., Ryckewaert, T., Firmin, N., Bertucci, F., Dufresne, A., Soulié, P., Perrin, C., Noal, S., Brahmi, M., Blay, J. Y., & Bompas, E. (2027). Deni Study: Real‐World Data on the Use of Nirogacestat in Patients With Desmoid Tumors in the French Sarcoma Group. International Journal of Cancer, 160(1), 161-170. https://doi.org/10.1002/ijc.70672
Vancouver
Kubicek P, Guérin-Charbonnel C, Toulmonde M, Boudou-Rouquette P, Thibaud V, Penel N, et al. Deni Study: Real‐World Data on the Use of Nirogacestat in Patients With Desmoid Tumors in the French Sarcoma Group. International Journal of Cancer. 2027;160(1):161-170. doi:10.1002/ijc.70672
BibTeX
@article{Kubicek2027,
author = {Kubicek, Pierre and Guérin-Charbonnel, Catherine and Toulmonde, Maud and Boudou-Rouquette, Pascaline and Thibaud, Valentin and Penel, Nicolas and Italiano, Antoine and Ryckewaert, Thomas and Firmin, Nelly and Bertucci, François and Dufresne, Armelle and Soulié, Patrick and Perrin, Christophe and Noal, Sabine and Brahmi, Mehdi and Blay, Jean-Yves and Bompas, Emmanuelle},
title = {Deni Study: Real‐World Data on the Use of Nirogacestat in Patients With Desmoid Tumors in the French Sarcoma Group},
journal = {International Journal of Cancer},
year = {2027},
volume = {160},
number = {1},
pages = {161--170},
doi = {10.1002/ijc.70672}
}
EUVIMED